Another Indian drugmaker cleared to produce TB drugs

31 October 2019

Even as a new vaccine is set to change the face of tuberculosis prevention, the TB Alliance has given the green light to Indian company Macleods Pharmaceuticals to manufacture the drug pretomanid, used to treat highly drug-resistant TB and as part of a regimen along with bedaquiline and linezolid, reports The Pharma Letter’s India correspondent.

This is the second generic company that has been given permission to manufacture the drug. The TB Alliance had granted rights to US drugmaker Mylan (Nasdaq: MYL) in April.

TB Alliance, the non-profit product development partnership and the generic manufacturer have agreed to produce the new TB drug for countries with high incidence of TB. However, manufacture of bedaquiline in India hit a wall recently. India is accessing the drug solely through the Bedaquiline Donation Program, a collaboration between the US Agency for International Development and American pharma giant Johnson & Johnson (NYSE: JNJ), which currently holds the patent for the drug.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK